Cronos Group Inc vs Palantir Technologies Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Palantir Technologies Inc trades at $209.05 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 404.8× Cronos Group Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Palantir Technologies Inc for 78 Days on average.
| CRON | PLTR | |
|---|---|---|
Market Cap | $1.18B | $477.68B |
Volume | 968,037 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $3.55 | $207.18 |
52-Week Low | $2.30 | $107.27 |
Typical Hold Time | 22 Days | 78 Days |
Enterprise Value | $387.62M | $468.48B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.23, down 0.31% with a bearish technical signal. Recent earnings show volatility with Q2 2026 beating expectations ($0.09 vs $0.01) but Q4 2025 missing. Revenue grew from $118M (2024) to $147M (2025), though net income turned negative at -$9M. The company maintains strong liquidity with $827M cash and no debt, highlighted in recent investor day presentations.
Outlook is mixed: analyst consensus leans Hold (60%) with cautious optimism on international expansion and margin improvements. Key risks include sustained negative cash flow (-$67M in 2025) and competitive pressures. Upside hinges on execution of growth initiatives in Canada and Europe, with profitability projections for 2026.
Palantir (PLTR) trades at $209.05, up 7.74% with strong bullish momentum as it approaches resistance at $209. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025, net income margin expanding to 36.3%, and consistent earnings beats. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support the upward trend, though valuation metrics remain elevated with P/E of 169.9 and P/S of 83.02.
Outlook remains positive given accelerating AI adoption and strong commercial growth (149% YoY US commercial revenue). Key risks include premium valuation sensitivity and competitive AI market pressures. Analyst consensus at $191.69 suggests potential near-term consolidation, but continued execution could justify higher multiples. Cash flow trends show strong operational performance despite significant investing outlays.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →